NEW YORK (GenomeWeb) – WuXi AppTec said today that it has signed an agreement with global information and communications technology provider Huawei to create cloud infrastructure for the China Precision Medicine Initiative.
According to Wuxi, the platform will leverage Huawei's capabilities and reach in the cloud infrastructure domain. The company serves 50,000 customers across China with data centers in 15 cities. The platform will also benefit from the genomics and precision medicine expertise of the WuXi AppTec subsidiary WuXiNextCode, whose technology already supports genomics-based efforts such as the UK's 100,000 Genomes Project, the Qatar Genome Project, as well as pediatric disease projects at the Children's Hospital of Fudan University and Boston Children's Hospital.
Also, the partners will follow established guidance from the China Food and Drug Administration and will work closely with unnamed third-party life science cloud providers to develop the data standards and exchange framework needed to support the China PMI, WuXi said.
"This partnership is a win-win-win for our companies and for the patients that will benefit from the vision of the China PMI," Hannes Smarason, WuXi NextCode's COO, said in statement. "We are thrilled to be deploying it with Huawei across China, a key part of our strategy to advance a global standard for turning the genome into better health."